Clinical Trials
14 trialsNCT01135329 2026-05-27
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT03856216 2026-04-15
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01532635 2025-05-04
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Thomas Jefferson University
Phase 2 Terminated
NCT03088709 2024-07-10
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
Phase 2 Terminated
NCT01044745 2023-09-06
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
Phase 2 Terminated
NCT04095858 2023-02-08
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01685411 2021-04-13
Busulfan and Cyclophosphamide Followed By ALLO BMT
Masonic Cancer Center, University of Minnesota
Phase NA Terminated
NCT00914940 2020-08-20
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT01116232 2019-03-26
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT00281879 2017-09-27
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00555048 2017-05-24
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01118013 2017-03-24
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT01621477 2017-02-20
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00579111 2016-05-04
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Baylor College of Medicine
Phase 1/2 Terminated